Drugs / interferon gamma
last change Dec 2023 re-read 2 minutes ago

interferon gamma

Protein / enzyme biologic

Developed for
melanoma · pneumonia · pulmonary tuberculosis · AIDS · anogenital human papillomavirus infection · cancer · candidemia · chronic granulomatous disease
+22 more · chronic hepatitis C virus infection · chronic prostatitis · coinfection · COVID-19 · cutaneous melanoma · fallopian tube cancer · hepatitis C virus infection · HIV infectious disease · leukocyte adhesion deficiency 1 · lung disorder · malignant epithelial tumor of ovary · malignant glioma · malignant mesothelioma · mycobacterial infectious disease · Mycobacterium avium complex disease · osteopetrosis · ovarian cancer · peritoneum cancer · prostate cancer · reactive arthritis · soft tissue sarcoma · infectious disease with sepsis
Investigated by
National Institute of Allergy and Infectious Diseases (NIAID) · SPP Pharmaclon Ltd. · National Cancer Institute (NCI) · InterMune · Aga Khan University · Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma
+27 more · BioMérieux · Bristol-Myers Squibb · Charite University, Berlin, Germany · Craig L Slingluff, Jr · DNAtrix, Inc. · FDA Office of Orphan Products Development · Fox Chase Cancer Center · Fred Hutchinson Cancer Center · French National Agency for Research on AIDS and Viral Hepatitis · Herbert Irving Comprehensive Cancer Center · Hoffmann-La Roche · Horizon Pharma Ireland, Ltd., Dublin Ireland · Hospices Civils de Lyon · Kirby Institute · M.D. Anderson Cancer Center · Medical University of South Carolina · Memorial Sloan Kettering Cancer Center · North-Western State Medical University named after I.I.Mechnikov · Northwell Health · Oregon Health and Science University · Presage Biosciences · Radboud University Medical Center · The University of New South Wales · University of Rochester · University of Washington · Virax Pty. Ltd, · dfg

Trials 27 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 16 trials
Phase 1 NCT03056599 Dec 2016 → Jul 2021 soft tissue sarcoma Presage Biosciences Completed No outcome recorded
Phase 1 NCT02614456 Dec 2015 → Jun 2019 cancer Fox Chase Cancer Center Completed No outcome recorded
Phase 1 NCT02197169 Sep 2014 → Mar 2018 malignant glioma DNAtrix, Inc. Completed No outcome recorded
Phase 1 NCT00977145 Nov 2009 → Oct 2012 melanoma Craig L Slingluff, Jr Terminated No outcome recorded
Phase 1 NCT00004016 Apr 1999 → ? cutaneous melanoma University of Rochester Completed No outcome recorded
Phase 1 NCT00004032 Oct 1997 → Apr 2004 malignant epithelial tumor of ovary National Cancer Institute (NCI) Completed No outcome recorded
Phase 1/23 trials
Phase 1/2 NCT05065905 Jan → Mar 2006 AIDS, coinfection, pulmonary tuberculosis SPP Pharmaclon Ltd. Completed No outcome recorded
Phase 1/2 NCT00332930 Sep 2002 → Sep 2003 HIV infectious disease Kirby Institute Completed No outcome recorded
Phase 1/2 NCT00002637 Jan 1995 → Feb 2001 prostate cancer Memorial Sloan Kettering Cancer Center Completed No outcome recorded
Phase 28 trials
Phase 2 NCT00148863 Jun 2004 → Aug 2007 chronic hepatitis C virus infection French National Agency for Research on AIDS and Viral Hepatitis Completed No outcome recorded
Phase 2 NCT00244179 Jan 2003 → ? reactive arthritis Charite University, Berlin, Germany Unknown No outcome recorded
Phase 2 NCT00501644 Jan 2003 → Jan 2009 fallopian tube cancer, ovarian cancer, peritoneum cancer M.D. Anderson Cancer Center Completed No outcome recorded
Phase 2 NCT00021567 Jul 2001 → Jun 2002 Mycobacterium avium complex disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 2 NCT00024271 May 2001 → ? malignant mesothelioma Herbert Irving Comprehensive Cancer Center Unknown No outcome recorded
Phase 2 NCT00001905 Apr 1999 → Mar 2002 leukocyte adhesion deficiency 1 National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 2 NCT00001407 May 1994 → May 2003 pneumonia, pulmonary tuberculosis National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 2 NCT00001318 Aug 1992 → Nov 2000 mycobacterial infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 2/31 trial
Phase 2/3 NCT00538811 hepatitis C virus infection Aga Khan University Completed No outcome recorded
Phase 36 trials
Phase 3 NCT05843786 Jun 2023 → Jul 2027 expected Hospices Civils de Lyon Recruiting No outcome recorded
Phase 3 NCT01270490 Jan 2011 → Jan 2013 candidemia Radboud University Medical Center Unknown No outcome recorded
Phase 3 NCT05156541 May 2009 → Jun 2010 anogenital human papillomavirus infection SPP Pharmaclon Ltd. Completed No outcome recorded
Phase 3 NCT05378646 Jan → Dec 2009 chronic prostatitis SPP Pharmaclon Ltd. Completed No outcome recorded
Phase 3 NCT00004402 Nov 1999 → Jun 2000 osteopetrosis FDA Office of Orphan Products Development Completed No outcome recorded
Phase 3 NCT00001296 Feb 1992 → Oct 2000 melanoma National Cancer Institute (NCI) Completed No outcome recorded
Phase 41 trial
Phase 4 NCT00001317 May 1992 → Jul 2001 chronic granulomatous disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase not applicable2 trials
NCT05054114 Dec 2020 → May 2021 COVID-19, lung disorder SPP Pharmaclon Ltd. Completed No outcome recorded
NCT05395702 May 2017 → Jul 2018 pneumonia SPP Pharmaclon Ltd. Completed No outcome recorded
Also used as a comparator or background therapy in 3 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 21 trial
Phase 2 NCT00006113 Background Jun 1999 → May 2003 cutaneous melanoma University of Southern California Terminated No outcome recorded
Phase 2/31 trial
Phase 2/3 NCT03984890 Background Aug 2019 → Dec 2021 chronic granulomatous disease Children's Hospital of Fudan University Completed No outcome recorded
Phase 31 trial
Phase 3 NCT01649921 Comparator Nov 2012 → Dec 2016 infectious disease with sepsis Radboud University Medical Center Completed No outcome recorded

Evidence & citations 19 cited values

Every value below carries the sentence it was read from. 32 sources stand behind the page.

FieldValueCited text
Known as interferon gamma “Recombinant interferon-gamma is a genetically engineered form of a substance normally produced by the body and is used to boost immune function.” NCT00001407
28

“Evaluating the Safety and the Biological Effects of Intratumoral Interferon Gamma and a Peptide-Based Vaccine in Patients With Melanoma” NCT00977145

“a single injection of DNX-2401 was followed by interferon gamma (IFN-γ).” NCT02197169

“Anti-tuberculosis drugs, interferon-gamma” NCT03984890

NCT00001317

NCT01649921

NCT00002637

NCT00006113

NCT00024271

NCT02614456

NCT00004032

NCT00244179

NCT00501644

NCT00001905

NCT01270490

NCT00021567

NCT05843786

NCT00001296

NCT00538811

NCT00001407

NCT00332930

NCT02197169

NCT00001318

NCT00004402

NCT05395702

NCT03056599

NCT00148863

NCT00004016

NCT05065905

Known as gamma interferon “In one or two patients on the drug, blood will be drawn frequently following one injection of gamma interferon (just before the injection and again at 0.25, 0.5, 1, 6, 12, 18,...” NCT00001407
Known as IFN-G “Tumor Necrosis Factor (Knoll), TNF, NSC-635257; Interferon gamma (Genentech), IFN-G, NSC-600662.” NCT00001296
5

IFN-g (interferon-gamma) 3 x 100 - 150 µg/week s.c. has been succesfully administered.” NCT00244179

“Interferon gamma human recombinant (IFN-G)” NCT05378646

“Interferon gamma human recombinant (IFN-G)” NCT05054114

“Interferon gamma human recombinant (IFN-G)” NCT05156541

“interferon gamma (IFN-G)” NCT00002637

Known as IFN-gamma “Recently, it has been shown that in vivo administration of interferon gamma (IFN-gamma) upregulates CD18 expression in normals and alters leukocyte trafficking.” NCT00001905
Known as IFN-y “HIV gag-pol antigens and interferon-gamma (IFN-y) in diluent” NCT00332930
Known as IFN-γ “The administration of interferon gamma (IFNγ) can restore the level of mHLA-DR and may possibly improve the prognosis as an adjuvant therapy associated to antibiotics.” NCT05843786
3

“adjunctive immune-stimulatory therapy with interferon-gamma (IFN-γ) may represent a promising candidate” PMID 24669841 Mar 2014

“a single injection of DNX-2401 was followed by interferon gamma (IFN-γ).” NCT02197169

“Interferon-gamma (IFN-γ): starting dose 50 mcg/m2 subcutaneously” NCT02614456

Known as Immukine “Interferon-gamma (Immukine, Boehringer-Ingelheim, Alkmaar, the Netherlands), 100mcg subcutaneously, on days 0-2-4-7-9-11.” NCT01649921
Known as Interferon gamma human recombinant ClinicalTrials.gov intervention name — accepted as the source's own label NCT05156541
2

NCT05054114

NCT05378646

Known as interferon gamma-1b “Group 1 will receive 500 micrograms of interferon gamma-1b 3 times a week for 48 weeks by inhalation.” NCT00021567
Known as NSC-600662 “Tumor Necrosis Factor (Knoll), TNF, NSC-635257; Interferon gamma (Genentech), IFN-G, NSC-600662.” NCT00001296
Known as recombinant interferon gamma “Biological: recombinant interferon gammaNCT00004032
Known as recombinant interferon gamma 1b recombinant interferon gamma 1b (rIFN-gamma1b)” PMID 19264351 Mar 2009
Known as rIFN-g rIFN-g (Interferon Gamma)” NCT00501644
Known as rIFN-gamma1b “interferon gamma 1b (rIFN-gamma1b)” PMID 19264351 Mar 2009
Known as rIFN-γ “treated with recombinant IFN-γ (rIFN-γ, 100 μg s.c., thrice a week) for 2 weeks” PMID 24669841 Mar 2014
Known as TG1041 “Adenovirus-Interferon- Gamma (TG1041)” NCT00004016
Action Activate “interferon gamma (IFN-gamma) upregulates CD18 expression in normals” NCT00001905
Modality Protein / enzyme biologic “Recombinant Human Gamma Interferon” NCT00001317
Route Subcutaneous subcutaneous injections of interferon-gamma” NCT00001317